VIR-1388 / Vir Biotech - LARVOL DELTA

A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

New P1 trial • Cytomegalovirus Infection • Human Immunodeficiency Virus • Infectious Disease

To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV (clinicaltrials.gov) - P1 | N=93 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed | Trial completion date: Nov 2027 ➔ Nov 2025

Trial completion • Trial completion date • Human Immunodeficiency Virus • Infectious Disease

To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV (clinicaltrials.gov) - P1 | N=95 | Active, not recruiting | Sponsor: Vir Biotechnology, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Human Immunodeficiency Virus • Infectious Disease

Phase 1 first-in-human study of VIR-1111, a prototype CMV-HIV vaccine vector (AIDS 2024) - P1, P1a | "BACKGROUND: Despite progress increasing antiretroviral treatment and PrEP utilization, HIV transmission persists globally. VIR-1111 was generally safe and well-tolerated in healthy participants. While VIR-1111 did not elicit sustained Gag-specific immune responses, a gene signature associated with vaccine responses was identified in 5/20 participants. This study provides foundational safety data supporting further CMV-HIV vaccine development."

P1 data • Cytomegalovirus Infection • Human Immunodeficiency Virus • Infectious Disease

To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV (clinicaltrials.gov) - P1 | N=95 | Recruiting | Sponsor: Vir Biotechnology, Inc. | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2023 ➔ Sep 2023

Enrollment open • Trial initiation date • Human Immunodeficiency Virus • Infectious Disease • CD4

To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV (clinicaltrials.gov) - P1 | N=95 | Not yet recruiting | Sponsor: Vir Biotechnology, Inc.

New P1 trial • Human Immunodeficiency Virus • Infectious Disease • CD4